Aa
A
A
Close
Avatar universal
Viral mutation data/telepravir

Recently I asked the study nurse at my site to ask for the viral mutation data from my prove 3 bloods.

I became low detectable during week 8 and it went up by week 12.
My last draw I was told would include a virus sequencing (to determine the mutuations I think).

I would like to have this info it could be important to know for my next attempt (if it is a protease tx and if there are the strong resistant virus type I can forget about it).

Has anybody got their viral mutation info from vertex?

I was told that she didn't get it, just the final Viral load.

Cheese
Cancel
10 Answers
Page 1 of 1
Avatar universal
Hi, I'm in the telaprevir study. I would like to hear more about your tx with telaprevir. Can you please post details of your experience. Thank you
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Avatar universal
hello copyman i am on rollover from prove 3 unblinded so far not bad 3 time relapser week 1 under 25 detected week 2 not detected waiting on week 3 and 4 results no rash as of yet in week 5 alot more itching then usual other then severe insomnia not bad
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Avatar universal
No, the nurse doesn't get it - and the nurse doesn't get it.  You  need to ask somebody higher up the food chain who understands the significance of your resistance data and is willing to go to Vertex and request it on your behalf.

dointime
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Avatar universal
thanks for that info. i'm in the 2nd part of the phase 3 study for naive patients.  the 2nd part study is "open label" so everyone knows they are getting the real drug. the only thing blinded is the viral loads.  May I ask what your starting VL was. Seems you are on your way to killing this dragon once and for all. best of luck
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Avatar universal
hi copyman screen was 2 million day one was1460000 1b viral was not that high had not rebounded from last treatment have relapsed from 72 weeks in 2004 best of luck to you
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Avatar universal
My experience with telaprevir is that it works well. I went undetectable by week 4 or so. Virus was back at week 8 test but very low. Week 12 it was a bit higher.

I did not develop rash but I did get itchy especially after exercise. Very itchy, EXTREMELY itchy.

As I was in rollover none of the data was blinded. I should be able to get any data on my mutation (or lack of) so I can decide on future treatment if it will work on me or not.

Good luck.
Cheese
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Avatar universal
Thanks Cheese,

I hope they give you the viral mutation data. I can't see them giving that info up easily. The last thing they want stock investors seeing is data that supports viral mutation. I don't think they want that type of data public just yeat. Good luck
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Avatar universal
hello cheese there is a ethics board at the hospital for this trial you should have there number on the paper you signed that may be a good place to start sorry for your bad luck regards steve
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Avatar universal
Vertex has been quite open about resistance to telaprevir and viral mutation.  Here's a study they published.:  
dointime


Evaluation of Viral Variants During a Phase 2 Study (PROVE2) of Telaprevir with Peginterferon alfa-2A and Ribavirin in Treatment-naïve HCV Genotype 1-Infected Patients
J. Pawlotsky5; T. Kieffer1; Y. Zhou1; E. Zhang1; M. Marcial1; R. Byrn1; T. Pfeiffer1; J. Miller1; A. Tigges1; D. Bartels1; A. Kwong1; P. Ferenci2; G. Dusheiko3; S. Zeuzem4
1. Infectious Diseases, Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA.
2. Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
3. Centre for Hepatology, Royal Free Hospital, London, United Kingdom.
4. Department of Medicine I, J.W. Goethe University Hospital, Frankfurt, Germany.
5. Department of Virology, Henri Mondor Hospital, University of Paris XII, Créteil, France.


Background: The VX05-950-104EU study (PROVE2) is a Phase 2 study of an HCV protease inhibitor, telaprevir (VX-950, TVR) 750 mg q8h, in combination with Peg-IFN-alfa-2a (P) 180 µg/week and ribavirin (R) 1000-1200 mg/day in treatment naive subjects with genotype 1 hepatitis C. Subjects were randomized into 4 groups that received: 1) TVR/P/R for 12 weeks, 2) TVR/P for 12 weeks, 3) TVR/P/R for 12 weeks followed by 12 weeks of P/R, and 4) P/R for 48 weeks (control group). Viral breakthrough (increase of > 1-log above HCV RNA nadir or increase to > 100 IU/mL in previously undetectable patients) was observed in some subjects during the first 12 weeks of therapy. Viral sequencing was used to evaluate the contribution of TVR resistance to antiviral response.

Methods: Plasma samples for viral sequencing were taken at baseline and at each HCV RNA assessment. The NS3-4A RNA region was amplified by nested RT-PCR and sequenced in samples with HCV RNA > 1,000 IU/mL. Prospectively defined criteria for identifying potential resistance mutations were applied using a Poisson distribution.

Results: HCV RNA was undetectable (LOD 10 IU/mL) at Week 4 in 14% of subjects in the P/R group, 74% in the TVR/P/R groups (p<0.001), and 53% in the TVR/P group (p<0.001); and at Week 12 in 43% of subjects in the P/R group, 79% in the TVR/P/R groups (p<0.001), and 63% in the TVR/P group (p<0.015). During the first 12 weeks on treatment, 6 of 152 subjects (4%) in the TVR/P/R groups, 19 of 76 subjects in the TVR/P group (25%), and 1 of 77 subjects (1%) in the P/R group had viral breakthrough. The breakthroughs were associated with wild-type virus in the P/R group and previously identified TVR-resistant variants in the TVR groups (TVR/P/R: genotype 1a, n=4: mainly V36M and R155K; genotype 1b, n=2: mainly A156T; TVR/P: genotype 1a, n=12: mainly V36M and R155K; genotype 1b, n=7: mainly V36A, T54A, R155K, and A156S/T).

Conclusions: In this interim analysis, TVR/P/R produced a significantly greater antiviral response at Weeks 4 and 12 compared to TVR/P and P/R in treatment naïve subjects with genotype 1 HCV. In the TVR groups, viral breakthroughs were associated with the selection of known TVR-resistant variants. The breakthrough rate in the TVR/P group was higher than in the TVR/P/R groups, suggesting that suboptimal inhibition of viral replication provides a greater probability for selection of TVR-resistant variants. Some subjects with viral breakthrough on TVR had a subsequent decline in HCV RNA during treatment with P/R, indicating that emergence of TVR-resistance does not preclude response to P/R.




Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Avatar universal
Yes, there is plenty of data about the viral mutations that are resistant to varying degrees to protease inhibitors including Telepravir. Nothing to hide here, it is well known.

What I would like to know is if anybody in the prove3 (or prove 2) were able to see their own personal results on any mutations that developed assuming they did not clear the virus of course.  

I do not want to cause a big stink at the ethics office, especially if it might reduce my chance at the next trial.
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Comment
Post Comment
Your Answer
Avatar universal
Answer
Do you know how to answer? Tap here to leave your answer...
Answer
Answer
Post Answer
A
A
Recent Activity
Avatar universal
Blank
317787 tn?1473362051
Blank
Dee1956 Meegy 172 days!! Coincidenc... Comment
Dec 01
406584 tn?1399591666
Blank
10356 commented on stilltrying1965's status
Dec 01
Blank
Weight Tracker
Track your weight over time
Start Tracking Now
Top Hepatitis Answerers
317787 tn?1473362051
Blank
DC
163305 tn?1333672171
Blank
Rural Mural, CA
446474 tn?1446351282
Blank
San Francisco, CA
Avatar universal
Blank
1747881 tn?1358189534
Blank
Greeley, CO
2059648 tn?1439770265
Blank
Hepatitis C Community Resources